^
    8ms
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1, N=174, Completed, Boehringer Ingelheim | Phase classification: P1a/1b --> P1
    Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    amredobresib (BI 894999)
    over1year
    Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours. (PubMed, Eur J Cancer)
    The 1.5, 2.5, and 6.0/3.0 mg doses in Schedules A, B, and C, respectively, were declared as maximum tolerated dose. Based on the strength of these data, BI 894999 was further evaluated in a Phase Ib trial.
    P1 data • Journal • Metastases
    |
    amredobresib (BI 894999)
    almost3years
    Pancreatic clonal replica tumors display functional heterogeneity in response to KRAS pharmacological inhibition and reveal unique epigenetic vulnerabilities to overcome resistance (AACR 2022)
    Our study suggests that pre-existing heterogeneous subclones with epigenetic plasticity contribute to escaping direct KRAS inhibition in pancreatic cancer and provides a new avenue to overcome such resistance by combining KRAS inhibitors with BET inhibitors.
    Late-breaking abstract
    |
    KRAS (KRAS proto-oncogene GTPase) • BRD3 (Bromodomain Containing 3)
    |
    KRAS mutation • KRAS G12C • KRAS G12D
    |
    Mekinist (trametinib) • MRTX1133 • BI-3406 • amredobresib (BI 894999)
    3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=174, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EGFR (Epidermal growth factor receptor)
    |
    amredobresib (BI 894999)
    over3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=174, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor)
    |
    amredobresib (BI 894999)
    over3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=204, Recruiting, Boehringer Ingelheim | Trial completion date: Aug 2022 --> Dec 2021 | Trial primary completion date: Jul 2022 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    amredobresib (BI 894999)
    over3years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=204, Recruiting, Boehringer Ingelheim | Trial primary completion date: Apr 2018 --> Jul 2022
    Clinical • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    amredobresib (BI 894999)
    over4years
    BI 894999 First in Human Dose Finding Study in Advanced Malignancies (clinicaltrials.gov)
    P1a/1b, N=176, Recruiting, Boehringer Ingelheim | Trial completion date: May 2021 --> May 2022
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    amredobresib (BI 894999)